BioMarin hosted a conference call Conference call to discuss results of the GALNS Phase 3 Trial was held on November 5 at 8:30 am and has a replay available from 10:30 am on November 5 through November 12. Webcast Link
BioMarin price target raised to $164 from $151 at JPMorgan JPMorgan analyst Cory Kasimov raised his price target for BioMarin to $164 saying the company "another solid quarter." The analyst sees "plenty of potential catalysts into year end" and keeps an Overweight rating on the stock.
BioMarin price target raised to $168 from $163 at Piper Jaffray Piper Jaffray analyst Joshua Schimmer raised his price target for BioMarin to $168 following the company's Q2 results. The quarter "was fine," Schimmer tells investors. He views the December 27 FDA action date for the company's Duchenne Muscular Dystrophy treatment drisapersen as one of the "most impactful binary events in large cap biotech through yearend." Schimmer thinks BioMarin's track record gaining FDA approval for Orphan drugs combined with the unmet need and the supportive dataset bodes well for approval. His valuation now includes nearly $50 per share for drisapersen. He keeps an Overweight rating on BioMarin.